Ondine Biomedical Inc.

Ondine Biomedical Inc. develops light-activated antimicrobial therapies, primarily focusing on its lead product, Steriwave®, which is designed for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. The company operates in the life sciences sector, generating revenue through the commercialization of its photodisinfection technology, which is authorized for nasal decolonization in Canada and certain international markets. Ondine's business model includes conducting clinical trials, such as the Phase 3 LANTERN study in the U.S., and expanding its presence in hospitals and surgical clinics across North America and Europe.

Ondine Biomedical Inc. develops light-activated antimicrobial therapies, primarily focusing on its lead product, Steriwave®, which is designed for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. The company operates in the life sciences sector, generating revenue through the commercialization of its photodisinfection technology, which is authorized for nasal decolonization in Canada and certain international markets. Ondine's business model includes conducting clinical trials, such as the Phase 3 LANTERN study in the U.S., and expanding its presence in hospitals and surgical clinics across North America and Europe.